伊鲁阿克作为新一代ALK抑制剂，具有强效抑制ALK激酶活性、良好覆盖常见耐药突变、优异血脑屏 障穿透能力等多重优势。临床研究显示，其在颅内病灶缓解方面表现突出，颅内客观缓解率(ORR)达 85.7%，为易发生脑转移的ALK阳性患者提供了重要治疗保障。同时，该药在长期生存数据上也展现出 1月12日，齐鲁制药旗下1.1类创新药、ALK阳性非小细胞肺癌靶向治疗新药——启欣可®(伊鲁阿克片) 在京东健康全网首发。该药物的上市，进一步丰富了京东健康在肺癌精准治疗领域的产品矩阵，为更多 ALK阳性肺癌患者提供了全新的治疗选择。京东健康将持续发挥"新特药全网首发第一站"的能力优势， 推动更多前沿治疗药物快速触达患者，提升药品可及性与治疗规范性。 肺癌是我国发病率和死亡率最高的恶性肿瘤，其中非小细胞肺癌(NSCLC)占比超过80%。ALK融合基因 突变在非小细胞肺癌中发生率约为3%-7%，主要出现在年轻人、女性及非吸烟者中，因其对靶向药物响 应率高、患者生存获益显著而被称为"钻石突变"。尽管靶向药物已成为ALK阳性肺癌的主要治疗手段， 但临床上仍面临着患者发病年龄轻，疗效需要持续突破、脑转移发生率高、耐药机制复杂等挑战。 除 ...

Core Viewpoint - The announcement highlights the breakthrough therapy designation granted to JSKN003, a targeted HER2 bispecific antibody-drug conjugate, for treating HER2-positive metastatic colorectal cancer patients who have failed previous treatments [1][4]. Group 1: Company Developments - Shanghai Jinmant Biotech, a subsidiary of the company, collaborates with Jiangsu Hengrui Medicine Co., Ltd. to develop JSKN003 [1]. - JSKN003 has received its second breakthrough therapy designation, previously granted for treating platinum-resistant recurrent epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer [4]. - The ongoing clinical studies for JSKN003 include multiple Phase II and III trials for treating breast cancer, ovarian cancer, and gastric cancer in China [4]. Group 2: Industry Context - Colorectal cancer is one of the most common malignancies globally, with 1.9262 million new cases and 903,900 deaths reported in 2022, ranking third in incidence and second in mortality among all cancers [2]. - In China, colorectal cancer has a high incidence rate, with over 500,000 new cases annually, making it the second most common cancer after lung cancer [2]. - Current approved treatments for HER2-positive metastatic colorectal cancer in China show limited efficacy, with median progression-free survival (mPFS) of only 2-3.7 months and median overall survival (mOS) of 7-10 months [2]. Group 3: Clinical Research Findings - Preliminary clinical research results for JSKN003 indicate significant efficacy and safety in treating HER2-positive metastatic colorectal cancer, with an objective response rate (ORR) of 61.9% and disease control rate (DCR) of 95.2% among patients who had at least one tumor efficacy assessment [3]. - The median progression-free survival (mPFS) for colorectal cancer patients treated with JSKN003 was reported at 13.77 months, with a median duration of response (mDoR) of 12.06 months [3]. - Safety data from the Phase II recommended dose cohort showed that only 14.0% of patients experienced grade 3 or higher treatment-related adverse events (TRAEs), with no treatment-related deaths reported [3].